Haemonetics (HAE) Tops Q3 EPS by 2c; updates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $127.42 +5.94%
Revenue Growth %: +5.6%
Financial Fact:
Gross profit: 104.25M
Today's EPS Names:
CIX, ARIS, COHR, More
Revenue Growth %: +5.6%
Financial Fact:
Gross profit: 104.25M
Today's EPS Names:
CIX, ARIS, COHR, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q3 EPS of $1.19, $0.02 better than the analyst estimate of $1.17. Revenue for the quarter came in at $349 million versus the consensus estimate of $352.98 million.
GUIDANCE:
Haemonetics sees FY2025 EPS of $4.50-$4.70, versus the consensus of $4.59.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- CompX International (CIX) Reports Q3 EPS of $0.44
- FatPipe, Inc. (FATN) Reports Q3 EPS of $0.09
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
